Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 18/20 | 0.49 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4964889 | 0.87 | PSIP1 (0.50) | PTGES2PSIP1 | |
| SCHEMBL4965334 | 0.84 | PSIP1 (0.55) | PTGES2PSIP1ALDH1A1 | |
| SCHEMBL15747320 | 0.76 | PTGES2 (0.41) | PTGES2 | |
| SCHEMBL4967201 | 0.72 | TSHR (0.37) | PTGES2MEN1LMNAMAPTHPGD | |
| SCHEMBL4965347 | 0.70 | TSHR (0.36) | PTGES2MEN1LMNAMAPTHPGD | |
| SCHEMBL12459797 | 0.69 | PSIP1 (0.77) | PSIP1MAPT | |
| SCHEMBL15672937 | 0.68 | PSIP1 (0.75) | PTGES2PSIP1ALDH1A1LMNAMAPT | |
| SCHEMBL2560634 | 0.67 | NOS3 (0.44) | MEN1ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL15740391 | 0.67 | NOS3 (0.42) | PTGES2ALDH1A1MAPT | |
| SCHEMBL3712510 | 0.66 | PSIP1 (1.00) | PSIP1ALDH1A1LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171737-A1 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2008073956-A2 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171737-A1 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | PTGES2 1609/4885PSIP1 1605/4885MEN1 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.